Roca Suarez Armando Andres, Zoulim Fabien
INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France.
University of Lyon, Université Claude-Bernard (UCBL), Lyon, France.
eGastroenterology. 2023 Oct 25;1(2):e100021. doi: 10.1136/egastro-2023-100021. eCollection 2023 Sep.
In spite of the fact that safe and effective vaccines have been available for over 40 years, hepatitis B virus (HBV) remains a major public health problem, as there are 296 million chronically HBV-infected individuals worldwide and 820 000 HBV-related deaths taking place every year. Achieving the goal of HBV cure remains a challenge due to the particularities of the HBV cycle underlying viral persistence. The new understanding of HBV biology and antiviral immune responses has allowed to identify novel drug targets. This has led to a renewed interest in developing new curative strategies and combinations for HBV. In the present review, we aim to summarise the biological and clinical challenges associated with chronic HBV infection. Moreover, we consider the lessons that have been learnt in the past years regarding the preclinical and clinical evaluation of compounds against HBV and how this is driving the field to explore new directions.
尽管安全有效的乙肝疫苗已经问世40多年，但乙肝病毒（HBV）仍然是一个重大的公共卫生问题，因为全球有2.96亿人长期感染HBV，每年有82万人死于HBV相关疾病。由于HBV循环导致病毒持续存在的特殊性，实现乙肝治愈的目标仍然是一项挑战。对HBV生物学和抗病毒免疫反应的新认识有助于确定新的药物靶点。这使得人们对开发新的乙肝治愈策略和联合疗法重新产生了兴趣。在本综述中，我们旨在总结与慢性HBV感染相关的生物学和临床挑战。此外，我们还考虑了过去几年在抗HBV化合物的临床前和临床评估方面所吸取的经验教训，以及这如何推动该领域探索新的方向。
